Nonetheless, anti-EGFR therapy is less effective in breast cancer than in lung, colon, head, and neck cancers [4] and there is therefore the need to fully understand the mechanisms underlying EGFR regulation to design novel targeted strategies. This evidence concerns the gene EGFR and malignant tumor of neck.